The global acne medication market size was estimated to be around US$ 11.57 billion in 2023 and is projected to reach US$ 19.17 billion by 2033, indicating a CAGR of 5.18% from 2024 to 2033.
Key Points
- North America dominated the acne medication market with the largest share of 45% in 2023.
- Asia Pacific is expected to witness significant growth in the market during the forecast period.
- By product, the antibiotics segment dominated the market in 2023.
- By product, the retinoid segment is expected to grow at a notable rate in the market during the forecast period.
- By routes of administration, the topical segment held the largest share of the market in 2023.
- By route of administration, the oral segment is expected to grow at the fastest rate in the market during the anticipated period.
- By age group, the 18-44 segment dominated the market with significant revenue in 2023.
- By distribution channel, the retail and online segment is expected to witness a significant rate of growth during the forecast period.
The market research report on the acne medication market provides a comprehensive analysis of various key aspects. It includes the definition, classification, and application of acne medication products. The report examines the development trends, competitive landscape, and industrial chain structure within the industry. Furthermore, it presents an overview of the industry, analyzes national policies and planning, and offers insights into the latest market dynamics and opportunities at a global level.
Get a Sample: https://www.precedenceresearch.com/sample/3924
Acne Medication Market Scope
Report Coverage | Details |
Growth Rate from 2024 to 2033 | CAGR of 5.18% |
Global Market Size in 2023 | USD 11.57 Billion |
Global Market Size by 2033 | USD 19.17 Billion |
U.S. Market Size in 2023 | USD 3.64 Billion |
U.S. Market Size by 2033 | USD 6.04 Billion |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Segments Covered | By Product, By Routes of Administration, By Age-Group, and By Distribution Channel |
Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Dental Implants and Abutment Systems Market Size Report by 2033
The report presents the volume and value-based market size for the base year 2023 and forecasts the market’s growth between 2023 and 2032. It estimates market numbers based on product form and application, providing size and forecast for each application segment in both global and regional markets.
Focusing on the global acne medication market, the report highlights its status, future forecasts, growth opportunities, key market players, and key market regions such as the United States, Europe, and China. The study aims to present the development of the acne medication market by considering factors like Year-on-Year (Y-o-Y) growth, in addition to Compound Annual Growth Rate (CAGR). This approach enables a better understanding of market certainty and the identification of lucrative opportunities.
Regarding production, the report investigates the capacity, production, value, ex-factory price, growth rate, and market share of major manufacturers, regions, and product types. On the consumption side, the report focuses on the regional consumption of acne medication products across different countries and applications.
Buyers of the report gain access to verified market figures, including global market size in terms of revenue and volume. The report provides reliable estimations and calculations for global revenue and volume by product type from 2024 to 2033. It also includes accurate figures for production capacity and production by region during the same period.
The research includes product parameters, production processes, cost structures, and data classified by region, technology, and application. Furthermore, it conducts SWOT analysis and investment feasibility studies for new projects.
This in-depth research report offers valuable insights into the acne medication market. It employs an objective and fair approach to analyze industry trends, supporting customer competition analysis, development planning, and investment decision-making. The project received support and assistance from technicians and marketing personnel across various links in the industry chain.
The competitive landscape section of the report provides detailed information on xx market competitors. It includes company overviews, financials, revenue generation, market potential, research and development investments, new market initiatives, global presence, production sites, production capacities, strengths and weaknesses, product launches, product range, and application dominance. However, the data points provided only focus on the companies’ activities related to the acne medication market.
Prominent players in the market are expected to face tough competition from new entrants. Key players are targeting acquisitions of startup companies to maintain their dominance. The report
Reasons to Purchase this Report:
- Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
- In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
- Market size in USD million and volume in million units provided for each segment and sub-segment.
- Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
- Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.
Acne Medication Market Players
- Galderma S.A.
- Bausch Health Companies Inc.
- Mayne Pharma Group Limited
- Teva Pharmaceutical Industries Ltd
- Almirall Sa
- Glaxosmithkline Plc (Gsk)
- Pfizer Inc.
- Mylan N.V.
- Sun Pharmaceutical Industries Limited
- Johnson & Johnson
Segments Covered in the Report
By Product
- Antibiotics
- Retinoids
- Isotretinoin
By Routes of Administration
- Topical
- Oral
By Age-group
- 18-44 years
- 10-17 years
- 45-65 years
- 65 years and above
By Distribution Channel
- Retail and Online
- Hospital
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Acne Medication Market
5.1. COVID-19 Landscape: Acne Medication Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Acne Medication Market, By Product
8.1. Acne Medication Market Revenue and Volume Forecast, by Product, 2024-2033
8.1.1. Antibiotics
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Retinoids
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
8.1.3. Isotretinoin
8.1.3.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 9. Global Acne Medication Market, By Routes of Administration
9.1. Acne Medication Market Revenue and Volume Forecast, by Routes of Administration, 2024-2033
9.1.1. Topical
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Oral
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 10. Global Acne Medication Market, By Age-group
10.1. Acne Medication Market Revenue and Volume Forecast, by Age-group, 2024-2033
10.1.1. 18-44 years
10.1.1.1. Market Revenue and Volume Forecast (2021-2033)
10.1.2. 10-17 years
10.1.2.1. Market Revenue and Volume Forecast (2021-2033)
10.1.3. 45-65 years
10.1.3.1. Market Revenue and Volume Forecast (2021-2033)
10.1.4. 65 years and above
10.1.4.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 11. Global Acne Medication Market, By Distribution Channel
11.1. Acne Medication Market Revenue and Volume Forecast, by Distribution Channel, 2024-2033
11.1.1. Retail and Online
11.1.1.1. Market Revenue and Volume Forecast (2021-2033)
11.1.2. Hospital
11.1.2.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 12. Global Acne Medication Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Product (2021-2033)
12.1.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)
12.1.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)
12.1.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
12.1.5.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)
12.1.5.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)
12.1.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
12.1.6.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)
12.1.6.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)
12.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Product (2021-2033)
12.2.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)
12.2.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)
12.2.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
12.2.5.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)
12.2.5.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)
12.2.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
12.2.6.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)
12.2.6.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)
12.2.6.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
12.2.7.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)
12.2.7.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)
12.2.7.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Product (2021-2033)
12.2.8.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)
12.2.8.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)
12.2.8.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Product (2021-2033)
12.3.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)
12.3.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)
12.3.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
12.3.5.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)
12.3.5.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)
12.3.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
12.3.6.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)
12.3.6.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)
12.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
12.3.7.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)
12.3.7.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)
12.3.7.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Product (2021-2033)
12.3.8.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)
12.3.8.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)
12.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
12.4.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)
12.4.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)
12.4.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
12.4.5.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)
12.4.5.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)
12.4.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
12.4.6.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)
12.4.6.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)
12.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
12.4.7.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)
12.4.7.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)
12.4.7.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Product (2021-2033)
12.4.8.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)
12.4.8.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)
12.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
12.5.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)
12.5.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)
12.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
12.5.5.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)
12.5.5.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)
12.5.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
12.5.6.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)
12.5.6.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)
12.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
Chapter 13. Company Profiles
13.1. Galderma S.A.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Bausch Health Companies Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Mayne Pharma Group Limited
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Teva Pharmaceutical Industries Ltd
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Almirall Sa
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Glaxosmithkline Plc (Gsk)
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Pfizer Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Mylan N.V.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Sun Pharmaceutical Industries Limited
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Johnson & Johnson
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/